Pulmonary Disease, Chronic Obstructive Clinical Trial
Official title:
Exercise and Disability in COPD Patients
Chronic obstructive pulmonary disease (COPD) is a chronic lung disease. Symptoms include shortness of breath, wheezing, and difficulty exercising. Increasing exercise and physical activity may relieve the symptoms of COPD and may also slow the progression of the disease. The purpose of this study is to evaluate the effectiveness of a lifestyle activity program versus a traditional exercise program at increasing the amount of physical activity among individuals with COPD.
COPD is a disease in which the lung airways are partly damaged and obstructed, making it
difficult to breathe. It is the fourth leading cause of death in the United States.
Cigarette smoking is the most common cause of COPD; however, breathing in other types of
lung irritants, including pollution, dust, and chemicals, over a long period of time may
also cause or contribute to COPD. The primary symptoms of COPD, exercise intolerance and
shortness of breath, often result in physical activity limitations, which may lead to a
decreased quality of life. While COPD is a chronic, incurable disease, individuals who
incorporate exercise and physical activity into their daily lifestyle may reduce the
symptoms and slow the progression of the disease. The purpose of this study is to compare
the effectiveness of an overall lifestyle activity program versus a traditional exercise
program on physical activity in individuals with COPD. The study will also evaluate the
impact of the two programs on exercise capacity, physical function, self-reported
disability, and health-related quality of life.
Participants with COPD will be randomly assigned to either an 11-month lifestyle activity
program or a traditional 3-month exercise program. The lifestyle activity program will
consist of 35 exercise and counseling sessions spaced over 11 months. This program will use
cognitive-behavioral strategies to encourage physical activity at home. Participants will
receive information on how to deal with COPD symptoms (including shortness of breath),
goal-setting, social support, and motivation. Participants will also receive follow-up
telephone calls from the program staff for additional support. The 3-month exercise program
will consist of 36 1-hour exercise training sessions, conducted 3 times a week for 12 weeks.
All participants will attend 4 baseline study visits at which their medical history will be
reviewed and standardized questionnaires will be completed to assess mood, depression,
social factors, COPD symptoms, and physical activity levels. Participants will undergo a
physical examination; a blood draw for laboratory testing; and spirometry, lung function,
exercise, and strength tests. These measures will be assessed again at 3, 6, and 12 months;
the 3- and 12-month assessments will occur over four study visits, and the 6-month
assessment will occur over two study visits.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05043428 -
The Roles of Peers and Functional Tasks in Enhancing Exercise Training for Adults With COPD
|
N/A | |
Completed |
NCT00528996 -
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.
|
Phase 2 | |
Completed |
NCT03740373 -
A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate
|
Phase 1 | |
Completed |
NCT05402020 -
Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan
|
||
Completed |
NCT05393245 -
Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data
|
||
Completed |
NCT04011735 -
Re-usable Respimat® Soft MistTM Inhaler Study
|
||
Enrolling by invitation |
NCT03075709 -
The Development, Implementation and Evaluation of Clinical Pathways for Chronic Obstructive Pulmonary Disease (COPD) in Saskatchewan
|
||
Completed |
NCT03764163 -
Image and Model Based Analysis of Lung Disease
|
Early Phase 1 | |
Completed |
NCT00515268 -
Endotoxin Challenge Study For Healthy Men and Women
|
Phase 1 | |
Completed |
NCT04085302 -
TARA Working Prototype Engagement Evaluation: Feasibility Study
|
N/A | |
Completed |
NCT03691324 -
Training of Inhalation Technique in Hospitalized Chronic Obstructive Pulmonary Disease (COPD) Patients - a Pilot Study
|
N/A | |
Completed |
NCT02236611 -
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT00153075 -
Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT01017952 -
A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT01009463 -
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT04882124 -
Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD
|
Phase 2 | |
Completed |
NCT02853123 -
Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients
|
Phase 4 | |
Completed |
NCT02619357 -
Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & Asthma
|
Phase 1 | |
Recruiting |
NCT05858463 -
High Intensity Interval Training and Muscle Adaptations During PR
|
N/A | |
Not yet recruiting |
NCT05032898 -
Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study Stage II
|